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Edited by Sandro SonninoAbstract Pleiotrophin (PTN) plays diverse roles in cell growth
and diﬀerentiation. In this investigation, we demonstrate that
PTN plays a negative role in adipogensis and that glycogen syn-
thase kinase 3b (GSK-3b) and b-catenin are involved in the reg-
ulation of PTN-mediated preadipocyte diﬀerentiation. Knocking
down the expression of PTN using siRNA resulted in an increase
in phospho-GSK-3b expression, and the accumulation of nuclear
b-catenin, which are critical downstream signaling proteins for
both the PTN and Wnt signaling pathways. Our investigation
suggests that there is a PTN/PI3K/AKT/GSK-3b/b-catenin sig-
naling pathway, which cross-talks with the Wnt/Fz/GSK-3b/b-
catenin pathway and negatively regulates adipogenesis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Pleiotrophin (PTN) is an 18-kDa heparin-binding growth
factor with pleiotrophic eﬀects. As a highly conserved cyto-
kine, PTN belongs to a new family of heparin-binding factors
which includes midkine, and shares 50% of sequence homology
with midkine [1–4]. PTN expression is extensively regulated in
embryonic development in a temporal and cell type-speciﬁc
manner, primarily in the nervous, cartilage, and vascular sys-
tems, but is downregulated in the adult [5–7]. Constitutive
expression of PTN in adults is limited to cells such as testicular
Leydig cells, uterine cells, and discrete populations of glia and
neurons [8–11]. However, there are exceptions: PTN gene
expression is upregulated in the adult brain after ischemic in-
jury and in cells stimulated by platelet-derived growth factor
[12,13]. It is also known that hormones such as estrogen and
testosterone are regulators of PTN gene expression [14].Abbreviations: PTN, pleiotrophin; GSK-3b, glycogen synthase kinase
3b; PPARc, peroxisome proliferator-activated receptor c; M, meth-
ylisobutylxanthine; D, dexamethasone; I, insulin; RTPT, receptor
protein tyrosine phosphatase; Fz, frizzled receptor; LRP, low density
lipoprotein receptor-related protein; TCF/LEF, T-cell factor/lym-
phoid-enhancing factor; PI3K, phosphoinositide 3-kinase; GRE, glu-
cocorticoid response element
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doi:10.1016/j.febslet.2006.12.043PTN regulates pleiotrophic functions, including mitogenesis,
angiogenesis, and diﬀerentiation. As a growth factor, PTN
stimulates mitogenesis of ﬁbroblasts, endothelial cells, and epi-
thelial cells in culture, as well as neurite outgrowth in neonatal
neuronal cells [10,15,16]. As a potent proto-oncogene, a rate-
limiting angiogenic factor during tumor growth, and a poten-
tial tumor promoter, PTN transforms NIH 3T3 cells and is
highly expressed in various tumor cell lines and tumor tissues,
such as in breast cancer, melanoma, pancreatic cancer, pros-
tate cancer, and colon cancer [17–21]. PTN also induces diﬀer-
entiation of oligodendrocyte progenitors and regulates
branching morphogenesis of the ureteric bud during develop-
ment of the kidney [4,22]. However, it is not clear if PTN is
also involved in adipocyte diﬀerentiation.
In a previous assay looking at the gene expression proﬁle of
preadipocyte diﬀerentiation, we found that PTN expression
varied with preadipocyte diﬀerentiation. This suggests that
PTN might also be a regulator of adipogenesis. In this investi-
gation, we study the role of PTN and the its related signaling
pathway in adipogenesis. This investigation provides some
insight into the mechanism of preadipocyte diﬀerentiation.2. Materials and methods
2.1. Cell culture and diﬀerentiation assays
3T3-L1 preadipocytes were cultured at 37 C with Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) supplemented with 10% calf serum
(CS) in a humid incubator containing 5% CO2. Adipogenesis was
induced with two diﬀerent ways. (A) Spontaneous diﬀerentiation:
After conﬂuence, 3T3-L1 cells were continuously cultured using
DMEM with 10% FBS for 14 days until some of the cells diﬀerentiated
to adipocytes. During this process, the cells were treated with either
an anti-PTN antibody at a concentration of 0.6 lg/ml (Santa Cruz
Biotechnology Inc., Santa Cruz, CA), siRNA targeting PTN, or with
recombinant PTN at a concentration of 50 ng/ml (EMD Biosciences,
Inc., San Diego, CA). (B) Induced diﬀerentiation: Two days after con-
ﬂuence, 3T3-L1 cells were induced to diﬀerentiate using the following
inducing mediums: 0.5 mM methylisobutylxanthine (M), 1 lM dexa-
methasone (D), and/or 1 lg/ml insulin(I) in DMEM with 10% FBS.
After day 2, the medium was replaced with DMEM containing 10%
FBS and 1 lg/ml insulin. After day 4, the cells were cultured in
DMEM containing 10% FBS without insulin [23].
2.2. siRNA transfection
SiRNA duplexes were synthesized by Shanghai GenePharma
Co. (Shanghai, China). PTN siRNA was designed according to the
characterization of siRNA by Elbashir and Reynolds [24,25], and tar-
gets the sequence 5 0-GCGGAGTCAAAGAAGAAGA-30 (GenBank
Accession No. NM_008973, 1918–1936), containing a sense strand
5 0-GCGGAGUCAAAGAAGAAGA dTdT-3 0 and an antisense strandblished by Elsevier B.V. All rights reserved.
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random sequence not targeting any known mammalian gene were used
as negative controls.
3T3-L1 preadipocytes were seeded into 6 well plates and cultured in
DMEM with 10% CS. The next day, the cells were transfected with the
siRNA duplexes at a concentration of 100 pmol/well, using Lipofect-
aime 2000 (Invitrogen Corp., Carlsbad, CA) according to manufac-
turer’s instructions. Six hours later, the medium was replaced with
DMEM containing 10% FBS. The cells were collected 24 h after trans-
fection for total RNA extraction or continuously cultured for sponta-
neous diﬀerentiation.
2.3. Oil Red-O staining of cytoplasmic triglycerides
On Day 14 (Spontaneous diﬀerentiation groups) or Day 11 (Induced
diﬀerentiation groups), 3T3-L1 cell monolayers were washed twice
with PBS and then ﬁxed with 10% formalin for 15 min. A 0.5% Oil
Red-O/isopropyl alcohol solution was added to the cells for 1 h, then
washed several times with distilled water. The stained cytoplasmic tri-
glycerides were visualized and photographed by microscope [26].
Finally, the stained cells were destained with isopropanol and the
OD of the destaining isopropanol was measured by spectrophotometry
at a wavelength 510 nm.
2.4. RT-PCR assay of PTN gene expression
Cells were lysed using TRIzol reagent (Invitrogen Corp.) and
total RNA was extracted according to the manufacturer’s protocol.
RT-PCR was performed with the total RNA using TaKaRa’s One
Step RNA PCR kit (TaKaRa Biotechnology, Dalian, China).
PTN expression was detected using a pair of primers, forward: 5 0-
ATGTCGTCCCAGCAATATCA-30; reverse: 5 0-ATCCAGCATCT-
TCTCCTGTTTC-3 0. PCR was carried out with the following
conditions: 94 C for 5 min, 27 cycles of 94 C for 1 min, 55 C for
1 min, 72 C for 1 min, and 72 C for 10 min. The PCR product was
about 504 bp in length, and the level of PTN expression was normal-
ized against the housekeeping gene glyceraldehyde-3-phosphate dehy-
drogenase (GADPH). The ampliﬁed fragment of GAPDH was
216 bp in length. PCR products were detected by agarose electropho-
resis and analyzed using Gel-Pro Analyzer (Media Cybernetics, Silver
Spring, MD).
2.5. Western blotting
Western blot analysis was done for PTN, phospho-GSK-3b, and
PPARc. 3T3-L1 preadipocytes were ﬁrst lysed using lysis buﬀer
(20 mM HEPES (pH 7.4), 1% Triton X-100, 2 mM EGTA, 2 mM
dithiothreitol, 50 mM b-glycerol phosphate, 1 mM sodium vanadate,
50 mM NaF, 10% glycerol, 1 mM phenylmethylsulfonylﬂuoride, and
a protease inhibitor cocktail). Whole cell lysates containing equalFig. 1. PTN expression during 3T3-L1 preadipocyte diﬀerentiation. 3T3-L1
after inducement. Total RNA and protein were extracted from the cell samp
PTN expression. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) wa
treated with methylisobutylxanthine, dexamethasone, and insulin.amounts of crude proteins were then separated in SDS–PAGE and
transferred to a nitrocellulose membrane. The membranes were stained
with primary antibody against PTN (Santa Cruz Biotechnology Inc.),
phospho-GSK-3b at serine 9 (Cell Signaling Technology Inc., Danvers,
MA), PPARc (Boster Biological Tech. Ltd., Wuhan, China), or
GAPDH (Kangchen Bio-tech, Shanghai, China), then incubated with
corresponding secondary antibodies (Kirkegaard & Perry Laborato-
ries, Inc., Gaithersburg, MD). After washing, the bound antibody
was visualized with an ECL blotting analysis system (Kirkegaard &
Perry Laboratories, Inc.).
Western Blotting of nuclear and cytosolic b-catenin was done by col-
lecting 3T3-L1 preadipocytes and extracting the nuclear and cytosolic
proteins using the Nuclear-Cytosol Extraction Kit (Tianlai Biomedical
Technology Co., China) according to the instructions of the manufac-
turer. These extracts were analyzed by Western blotting through SDS–
PAGE with an anti-b-catenin antibody (EMD Biosciences, Inc.) as the
primary probe.3. Results
3.1. PTN expression pattern during 3T3-L1 preadipocyte
diﬀerentiation
In a previous gene expression proﬁle assay of preadipocyte
diﬀerentiation, we found that PTN expression changed during
the course of preadipocyte diﬀerentiation. To further investi-
gate this pattern and its aﬀect on adipogensis, we collected
3T3-L1 cells at diﬀerent time points during 3T3-L1 diﬀerentia-
tion induced by methylisobutylxanthine, dexamethasone, and
insulin (MDI). The PTN expression pattern was determined
by RT-PCR (Fig. 1A) and Western blotting (Fig. 1B). Before
conﬂuence, PTN expression is maintained at a nearly undetect-
able level. It signiﬁcantly increases after conﬂuence, but
quickly deceases when diﬀerentiation is induced by MDI. This
expression pattern suggests that PTN may play a role in prea-
dipocyte diﬀerentiation, especially at conﬂuence.3.2. Dexamethasone enhances 3T3-L1 preadipocyte
diﬀerentiation by downregulating PTN expression
We found that PTN expression was downregulated 48 h
after MDI induction of 3T3-L1 preadipocyte diﬀerentiation
(Fig. 1). In order to identify the component or componentscells were collected before conﬂuence, 24 h after conﬂuence, and 48 h
les. RT-PCR (A) and Western blotting (B) were carried out to detect
s used as an internal control. NC: non-conﬂuent; C: conﬂuent; MDI:
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the eﬀect of PTN downregulation on MDI-induced diﬀerenti-
ation of 3T3-L1 preadipocytes, we treated conﬂuent 3T3-L1
preadipocytes with methylisobutylxanthine (M), dexametha-
sone (D), and insulin (I), both independently and in the com-
binations MD, DI, MI, and MDI. Two days later, the cells
were collected and PTN expression was detected with Western
blotting. Fig. 2A shows that PTN expression was repressed in
the cells treated with MDI, DI, MD, or D alone but not in cells
treated with MI, or M or I only. These results suggest that it is
dexamethasone that represses PTN expression. To investigate
the eﬀect of the dexamethasone-induced repression of PTN
expression on 3T3-L1 preadipocyte diﬀerentiation, cells trea-
ted with MDI, DI, MD, or MI as a control, were continuously
cultured for 4 days, then ﬁxed and stained with Oil Red-O. The
diﬀerentiation of MI-treated cells was the poorest compared
with all other treatments, showing a low adipocyte number
under the microscope and a poor degree of maturity, with
the lowest OD values measured from isoproponal elution of
Oil Red-O staining (Fig. 2B and C). Our results suggest that
3T3-L1 preadipocyte diﬀerentiation induced by dexametha-
sone is at least partially related to the downregulation of
PTN expression, and that PTN might play a negative role in
adipogenesis.
3.3. PTN inhibits 3T3-L1 preadipocyte diﬀerentiation through
downregulation of PPARc
To understand the role PTN plays during preadipocyte dif-
ferentiation, we designed two experiments: an anti-PTN anti-
body assay and a PTN-speciﬁc siRNA assay. These
experiments let PTN lost function or silence its expression in
3T3-L1 cells spontaneous diﬀerentiation model. After conﬂu-
ence, 3T3-L1 cells were continuously cultured and treated with
anti-PTN antibody. At Day 14, cells were stained with Oil Red-
O and photographed (Fig. 3A). PTN antibody-treated cells dif-
ferentiated much better than untreated cells, with an increase inFig. 2. Dexamethasone down-regulates PTN expression and stimulates 3T3-L
were induced to diﬀerentiate with MDI or the inducers in diﬀerent comb
inducement (A) or cells were continuously cultured and stained with Oil Re
stained cells was eluted with isoproponal, and the OD of the elution wa
methylisobutylxanthine, dexamethasone, and insulin; DI: dexamethasone
methylisobutylxanthine and insulin; M only: methylisobutylxanthine; I onlyadipocyte numbers and degree of maturity, as determined by
the size and number of Oil Red-O-stained cytoplasmic triglyc-
eride droplets. Subsequently, the stain was eluted with isoprop-
onal and the OD detected by spectrophotometry at 510 nm.
Fig. 3B shows that the OD of anti-PTN-treated samples is sig-
niﬁcantly higher than in untreated groups (Fig. 3B).
An siRNA duplex targeting PTN and a non-gene targeting
siRNA negative control with a random sequence were
designed and synthesized, and transfected into 3T3-L1 cells.
Knockdown of PTN was conﬁrmed by RT-PCR, using total
RNA extracted from 3T3-L1 cells collected 24 h after siRNA
transfection. The results suggest that PTN expression was
decreased by 80.5% in comparison with a negative control
(Fig. 4A). After 14 days, we found that siRNA transfection
enhanced preadipocyte diﬀerentiation, showing an increase in
the number of mature adipocytes and in the OD value of Oil
Red-O eluted by isoproponal from siRNA-transfected cells,
compared with control (Fig. 3A and B). The results of the
anti-PTN antibody assay and the PTN-speciﬁc siRNA assay
suggest that PTN may play a negative role in preadipocyte dif-
ferentiation. To further conﬁrm the inhibition of PTN in prea-
dipocyte diﬀerentiation, recombinant PTN was added into the
culture medium of 3T3-L1 cells at a concentration of 50 ng/ml.
Results show that recombinant PTN repressed the spontane-
ous diﬀerentiation of 3T3-L1 cells (Fig. 3A and B).
Peroxisome proliferator-activated receptor c (PPARc) is a
key transcription factor during adipocyte diﬀerentiation [26].
To investigate whether PTN mediated repression of adipogen-
sis through PPARc, we tested the expression of PPARc in cells
transfected with PTN siRNA. Our results showed that PPARc
expression was upregulated 48 h after siRNA transfection in
3T3-L1 cells, compared with control (Fig. 4B). These results
suggest that PTN represses adipogenesis by inhibiting PPARc
expression. However, it is not clear which signaling pathway
PTN acts through to downregulate PPARc expression and
adipogenesis.1 preadipocyte diﬀerentiation. Two days after conﬂuence, 3T3-L1 cells
inations. Cell lysate was collected for Western blotting 2 days after
d-O 6 days after inducement (B). Subsequently, the Oil Red-O in the
s detected by spectrophotometry at 510 nm (C). MDI: treated with
and insulin; MD: methylisobutylxanthine and dexamethasone; MI:
: insulin; D only: dexamethasone; Con: control.
Fig. 3. Adipogenesis was enhanced by anti-PTN antibody and siRNA targeting PTN, but inhibited by recombinant PTN in 3T3-L1 preadipocytes.
Conﬂuent cells treated with recombinant PTN or anti-PTN antibody, and PTN-speciﬁc siRNA transfected cells, were cultured for 14 days and the
cells stained with Oil Red-O and photographed (A). Subsequently, the Oil Red-O was eluted with isoproponal, and the OD of the elution was
detected by spectrophotometry at 510 nm (B). Anti-PTN: PTN antibody-treated cells; no-anti-PTN: cells without PTN antibody; SI: PTN-speciﬁc
siRNA-transfected cells; RS: random sequence siRNA-transfected cells; re-PTN: recombinant PTN-treated cells; no-re-PTN: cells without
recombinant PTN.
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of adipocyte diﬀerentiation
In our investigation, we determined that PTN repressed adi-
pocyte diﬀerentiation but did not know which signaling path-
way was involved. It had been previously reported that many
of PTN’s functions are regulated through b-catenin [1,27],
and its important role in Wnt-mediated repression of prea-
dipocyte diﬀerentiation has also been studied [26,28]. We
therefore speculated that b-catenin would play a role in
PTN-mediated regulation of adipocyte diﬀerentiation. 3T3-
L1 cells were collected and cytoplasmic and nuclear proteins
were isolated for Western blotting, in order to investigate the
expression and sub-cellular distribution of b-catenin during
3T3-L1 cell diﬀerentiation. We found that b-catenin was
mainly located in the cytoplasm and barely detectable in thenucleus of non-conﬂuent cells that had extremely low
PTN expression. In conﬂuent cells with high PTN expression,
nuclear accumulation of b-catenin was easily detected, while
cytoplasmic levels were also higher (Fig. 5A). This result sug-
gested that PTN may regulate 3T3-L1 cell diﬀerentiation
through the b-catenin signaling pathway. To conﬁrm this
hypothesis, siRNA was used to knock down PTN expression.
In conﬂuent cells, siRNA-mediated PTN knockdown
decreased both the cytoplasmic concentration and nuclear
accumulation of b-catenin (Fig. 5A).
The classical signaling pathway connecting PTN to b-cate-
nin is the PTN-RPTP b/f pathway [1,27]. RPTP is the recep-
tor (transmembrane) protein tyrosine phosphatase, and
activation of this pathway decreases cytoplasmic concentra-
tions of b-catenin. We had observed an increase in b-catenin
Fig. 4. PTN-speciﬁc siRNA knocks down PTN expression and down-regulates PPARc expression in 3T3-L1 cells. 3T3-L1 cells were transfected with
siRNA targeting PTN, and cells transfected with a non-targeting random sequence siRNA were used as control. Cells were collected 24 or 48 h after
transfection, and total RNA and protein were extracted. RT-PCR was carried out to detect expression of PTN (A). PPARc expression was
determined by Western blotting with a primary antibody against PPARc (B).
Fig. 5. The eﬀect of PTN on the nuclear accumulation of b-catenin
and phosphorylation of GSK-3b. The eﬀect of PTN on GSK-3b and b-
catenin was determined by Western blotting. Non-conﬂuent and
conﬂuent 3T3-L1 cells with or without siRNA transfection were
prepared for protein extraction. Nuclear and cytoplasmic proteins
were isolated with the Nuclear-Cytosol Extraction Kit, and b-catenin
expression checked using an anti-b-catenin antibody (A). Total protein
samples were also prepared from non-conﬂuent and conﬂuent 3T3-L1
cells with or without siRNA transfection, and the presence of
phospho-GSK-3b was detected using an anti-phospho-GSK-3b anti-
body. NC: non-conﬂuent 3T3-L1 cells; C: conﬂuent cells; SI: PTN-
speciﬁc siRNA-transfected cells; RS: random sequence siRNA-trans-
fected cells; Nu: nuclear protein; Cy: cytoplasmic protein.
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f pathway to explain PTN-mediated repression of adipocyte
diﬀerentiation. Instead, we believe that there is cross-talk
between the Wnt and PTN signaling pathways during prea-
dipocyte diﬀerentiation, as both these pathways play repres-
sive role through cytosolic accumulation and nuclear
translocation of b-catenin. In the Wnt signaling pathway, gly-
cogen synthase kinase 3b (GSK-3b) is a key molecule that
regulates cytosolic accumulation and nuclear translocation
of b-catenin [29]. We therefore speculated that GSK-3b could
be a point of intersection between the PTN and Wnt signal-
ing pathways. 3T3-L1 cells at diﬀerent conﬂuencies were col-
lected for Western blotting, and the results show that the
level of phospho-GSK-3b is enhanced in conﬂuent 3T3-L1cells with high levels of PTN expression, compared with
non-conﬂuent 3T3-L1 cells, which express extremely low lev-
els of PTN (Fig. 5B). PTN-mediated increase of phospho-
GSK-3b was further validated by siRNA-mediated PTN
knockdown, in which the decrease in PTN protein levels
caused a reduction in phospho-GSK-3b levels and in the
nuclear accumulation of b-catenin (Fig. 5B).4. Discussion
Adipose tissue is not only an important depot for energy
storage, but is also an endocrine organ that regulates energy
homeostasis by secreting diverse factors [30,31]. As one of
the most well-characterized and reliable models for studying
adipogenesis, 3T3-L1 cells can diﬀerentiate into adipocytes,
and has revealed many of the metabolic and endocrine func-
tions of adipocytes in vitro [23,31]. Diﬀerentiation of preadipo-
cytes is regulated by a balance of various factors that either
stimulate or inhibit diﬀerentiation. Upon reaching conﬂuence,
the balance may be tipped towards the inhibition of diﬀerenti-
ation through the activation of many inhibitors [26,32]. In our
investigation, we determined that PTN may be an inhibitor of
diﬀerentiation, and may be activated by cells signaling conﬂu-
ence or by other correlated factors, and may be repressed by
inducers of diﬀerentiation. PTN is barely expressed in 3T3-
L1 preadipocytes that are not conﬂuent, but is markedly
upregulated in conﬂuent cells. Moreover, this upregulation
can be signiﬁcantly suppressed by MDI induction of diﬀeren-
tiation. These characteristics are similar to many other diﬀer-
entiation inhibitors.
Diﬀerentiation assays demonstrated that treatment of 3T3-
L1 cells with MDI decreased PTN expression and sharply in-
duced adipocyte diﬀerentiation. Further experiments studying
the roles of the diﬀerent inducers showed that dexamethasone
is an inhibitor of PTN expression, and that it could act
whether alone or in combination with other inducers. Through
Fig. 6. Schematic representation of the cross-talk between the PTN
and Wnt/b-catenin signaling pathways to inhibit adipogensis. PTN
signals the PTN/PI3K/AKT/GSK-3b/b-catenin pathway to repress
adipogenesis through cross-talk with the Wnt/Fz/GSK-3b/b-catenin
pathway. Fz: frizzled; LRP: low density lipoprotein receptor-related
protein; Dsh: disheveled; TCF/LEF: T cell factor/1ymphoid enhancer
factor.
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glucocorticoid response elements (GRE), speciﬁcally ACA
TGC TGT (GenBank Accession No. U71456, 11–19). As a
glucocorticoid, dexamethasone might inhibit PTN expression
through the GRE.
The PTN-RPTP b/f-b-catenin pathway is the classical
signaling pathway for PTN, in which PTN is identiﬁed as
the ﬁrst natural ligand of the RPTP family [1,27,33]. The inter-
action of PTN with the transmembrane receptor induces
dimerization of the receptor, causes inactivity of the intrinsic
tyrosine phosphatase of RPTP b/f, increases steady-state
tyrosine phosphorylation of b-catenin, targets it for ubiqui-
tin-mediated degradation, and decreases the cytoplasmic con-
centration and nuclear accumulation of b-catenin in U373-
MG and Sf9 cells [27,33]. However, in PTN-mediated regula-
tion of adipogenesis, we found that PTN signaling increased
the cytoplasmic concentration and nuclear accumulation of
b-catenin in 3T3-L1 cells. The PTN-RPTP b/f pathway was
therefore unlikely to be involved in this regulation. The speciﬁc
signaling pathway is still unclear, but several clues point
to Wnt-mediated repression of adipocyte diﬀerentiation
[26,28,29,34].
Bennet et al. reported that disruption of extracellular Wnt
signaling could cause spontaneous adipocyte diﬀerentiation
[26]. We found that blocking PTN signaling enhanced sponta-
neous adipocytes diﬀerentiation. Both PTN and Wnt repress
adipocyte diﬀerentiation through cytosolic accumulation and
nuclear translocation of b-catenin, so it is possible that there
is cross-talk between the Wnt and PTN signaling pathways
during preadipocyte diﬀerentiation. To conﬁrm our hypothe-
sis, we searched for the molecule directly connected to both
pathways and found GSK-3b [21,29]. Wnt signals through
the frizzled receptor (Fz) and the low density lipoprotein recep-
tor-related protein (LRP) co-receptors [35,36]. When Wnt sig-
naling is active, GSK-3b is phosphorylated. Phospho-GSK-3b
loses its activity and allows cytosolic accumulation and nuclear
translocation of b-catenin. Once in the nucleus, b-catenin
binds to the T-cell factor/lymphoid enhancer factor (TCF/
LEF) family of transcription factors and activates transcrip-
tion of Wnt-regulated target genes [26,29,37,38]. In our
investigation, when PTN signaling is active, GSK-3b is also
phosphorylated, and causes cytosolic accumulation and nucle-
ar translocation of b-catenin. Our results suggest that PTN
regulates preadipocyte diﬀerentiation through cross-talk with
the Wnt signaling pathway during preadipocyte diﬀerentiation,
and that GSK-3b is the cross point between these two path-
ways.
GSK-3b is a critical downstream signaling protein for the
phosphoinositide 3-kinase (PI3K)/AKT pathway. It has been
reported that PTN can activate AKT through PI3K and
induce serine/threonine phosphorylation of downstream tar-
gets such as GSK-3b [16,39–41]. Phospho-GSK-3b loses its
phosphorylation activity, allowing b-catenin to accumulate in
the cytoplasm and translocate to the nucleus where it binds
to the TCF/LEF family and activates transcription of PTN-
regulated target genes. It may also inhibit the expression of
some target genes, such as PPARc [29,38], resulting in the
repression of preadipocyte diﬀerentiation. Our investigation
suggests that there is a PTN/PI3K/AKT/GSK-3b/b-catenin
signaling pathway, which cross-talks with the Wnt/Fz/GSK-
3b/b-catenin pathway and negatively regulates adipogenesis
(Fig. 6).Acknowledgment: This project is supported by National Natural Sci-
ence Foundation of China (No. 30470869).References
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